Click image to expand

NTM-006 is a New Chemical Entity with a Novel Mechanism of Action
  • Non-opioid, non-NSAID, non-gabapentinoid new chemical entity (NCE) with a novel mechanism of action (MOA) for once-daily, oral administration for the treatment of chronic pain.
  • In-licensed from J&J which developed the asset and conducted a phase IIa single-dose study demonstrating superior analgesic efficacy vs acetaminophen over 24 hours.
  • Preclinical evidence suggests NTM-006 exerts its analgesic activity via Adenosine A3 Receptor Modulation (ARM).
  • In development for chronic neuropathic/nociplastic pain with the potential to offer significant benefits as monotherapy or as part of a multimodal regimen based on:
    • Convenient once-daily, oral regimen.
    • Non-opioid that is non-scheduled, and devoid of opioid induced side-effects, respiratory depression and abuse potential.
    • Non-NSAID without the NSAID boxed warning or potentially serious NSAID related gastrointestinal, cardiovascular or bleeding side effects.
    • Non-gabapentinoid with more predictable efficacy and superior tolerability.

If approved, NTM-006 will provide patients, professionals and payers with a new, effective, non-opioid analgesic, with a novel MOA, and without the side-effects, risks, and liabilities of opioids, or the disadvantages of NSAIDs and gabapentinoids.

Disclaimer: NTM-006 is an investigational new drug candidate and is not approved for any indication in any market.